抗線溶薬の世界市場レポート 2025年

抗線溶薬市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5.8％で223億1,000万米ドルに成長します。予測期間の成長は、高齢者人口の増加、外傷症例の増加、低侵襲手術の拡大、分娩後出血の発生率の上昇、患者の安全性への注目の高まりなどに起因しています。予測期間における主な動向としては、個別化医療へのシフト、遠隔医療の採用拡大、バイオシミラー抗線溶薬の開発、手術中の予防的使用の増加、外傷治療におけるAIの統合などが挙げられます。

交通事故の発生率の増加は、今後の抗線溶薬市場の成長を促進すると予測されています。この交通事故の増加は、スマートフォンの使用、スピード違反、飲酒運転、車両の整備不良など、いくつかの要因に起因しています。抗線溶薬は、血栓を安定させ、過剰な出血を最小限に抑え、生存率を高めることで、交通事故被害者の出血管理に重要な役割を果たします。例えば、2024年4月、米国連邦政府機関である国家道路交通安全局（NHTSA）の報告書によると、2022年の漫然運転による死者数は3,308人、負傷者数は約28万9,310人で、そのうち621人が交通弱者であったことが明らかになりました。このデータは、死亡率の増加という厄介な事態を浮き彫りにしています。したがって、交通事故の発生率の上昇が抗線溶薬市場の成長を後押ししています。

外科手術の増加は、抗線溶薬市場の今後の成長を促進すると予想されます。外科手術が増加している背景には、医療技術の進歩、高齢化、意識の向上、文化的・社会的要因などがあります。抗線溶薬は、血栓の破壊を防ぐことで手術中の出血を抑え、止血効果を高め、輸血の必要性を減少させる可能性があります。例えば、米国を拠点とする美容整形外科医の専門団体である国際美容整形外科学会が2023年9月に発表した「Global Survey 2022」レポートによると、2022年の美容整形外科手術は全体で11.2％増加し、世界全体で1,490万件以上の手術が行われ、そのうち美容整形外科手術は4年間で41.3％増加し、脂肪吸引は2022年と2021年の両方で最も一般的な手術方法でした。したがって、手術件数の増加が抗線溶薬市場の成長を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界抗線溶薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の抗線溶薬市場：成長率分析
• 世界の抗線溶薬市場の実績：規模と成長, 2019-2024
• 世界の抗線溶薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界抗線溶薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の抗線溶薬市場：適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 婦人科
• 遺伝性血管性浮腫
• 線溶反応試験
• 手術
• その他の適応症
• 世界の抗線溶薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 注射剤
• オーラル
• トピック
• 世界の抗線溶薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院と診療所
• 外来手術センター
• 外傷センター
• 世界の抗線溶薬市場婦人科のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 月経過多（月経過多）
• 産後出血
• 子宮内膜症関連の出血
• 世界の抗線溶薬市場遺伝性血管性浮腫のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 遺伝性血管性浮腫の急性発作
• 遺伝性血管性浮腫の予防
• 世界の抗線溶薬市場線溶反応試験の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 外傷における線溶活性の検査
• 心臓外科における線溶反応検査
• 凝固障害の検査
• 世界の抗線溶薬市場、手術の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• 整形外科手術
• 心臓血管手術
• 歯科手術
• 脳神経外科
• 泌尿器科手術
• 世界の抗線溶薬市場、その他の適応症のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 外傷および傷害関連出血
• 術後出血管理
• 血友病関連の出血制御

第7章 地域別・国別分析

• 世界の抗線溶薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の抗線溶薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 抗線溶薬市場：競合情勢
• 抗線溶薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • DAIICHI SANKYO COMPANY LIMITED Overview, Products and Services, Strategy and Financial Analysis
  • Sun Pharmaceutical Industries Ltd Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Takeda Pharmaceuticals
• Aurobindo Pharma Limited
• Cipla Limited
• Intas Pharmaceuticals
• Lupin Limited
• Zydus Lifesciences Ltd.
• Hetero Drugs Limited
• Glenmark Pharmaceuticals
• Alkem Laboratories
• Torrent Pharmaceuticals Ltd
• Macleods Pharmaceuticals Pvt Ltd
• Mankind Pharma Ltd
• Emcure Pharmaceuticals Ltd
• Bharat Serums & Vaccines Ltd
• Systopic Laboratories Pvt Ltd

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 抗線溶薬市場2029：新たな機会を提供する国
• 抗線溶薬市場2029：新たな機会を提供するセグメント
• 抗線溶薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Antifibrinolytic drugs are medications designed to prevent the breakdown of blood clots by inhibiting enzymes such as plasmin, which are essential for controlling excessive bleeding. These drugs are used to treat or prevent bleeding in conditions such as hemophilia, heavy menstrual bleeding, and during surgeries where substantial blood loss is anticipated.

The primary indications for antifibrinolytic drugs include gynecology, hereditary angioedema, fibrinolytic response testing, surgeries, and other uses. In gynecology, which focuses on the female reproductive system, these drugs help manage bleeding issues associated with gynecological conditions or surgical procedures. Antifibrinolytic drugs can be administered through various routes, including injectable, oral, and topical methods. They are used by a range of end users, including hospitals and clinics, ambulatory surgical centers, and trauma centers.

The antifibrinolytic drugs market research report is one of a series of new reports from The Business Research Company that provides antifibrinolytic drugs market statistics, including antifibrinolytic drugs industry global market size, regional shares, competitors with a antifibrinolytic drugs market share, detailed antifibrinolytic drugs market segments, market trends and opportunities, and any further data you may need to thrive in the antifibrinolytic drugs industry. This antifibrinolytic drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The antifibrinolytic drugs market size has grown strongly in recent years. It will grow from $16.82 billion in 2024 to $17.84 billion in 2025 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to the increasing prevalence of bleeding disorders, rising number of surgical procedures, increasing use in dental surgeries, higher incidence of cardiovascular diseases, and improving access to healthcare services.

The antifibrinolytic drugs market size is expected to see strong growth in the next few years. It will grow to $22.31 billion in 2029 at a compound annual growth rate (CAGR) of 5.8%. The growth in the forecast period can be attributed to the increasing geriatric population, growing number of trauma cases, expansion of minimally invasive surgeries, rising incidence of postpartum hemorrhage, and increasing focus on patient safety. Major trends in the forecast period include a shift towards personalized medicine, growing adoption of telemedicine, development of biosimilar antifibrinolytics, rise in prophylactic use during surgeries, and integration of AI in trauma care.

The increasing incidence of road accidents is projected to drive the growth of the antifibrinolytic drugs market in the future. This rise in road accidents can be attributed to several factors, including the use of smartphones, speeding, driving under the influence, and poor vehicle maintenance. Antifibrinolytic drugs play a crucial role in managing bleeding among road accident victims by stabilizing blood clots, minimizing excessive bleeding, and enhancing survival rates, making them essential in trauma care to prevent significant blood loss. For example, in April 2024, a report from the National Highway Traffic Safety Administration (NHTSA), a US federal agency, revealed that distracted driving was responsible for 3,308 fatalities and approximately 289,310 injuries in 2022, with 621 of those deaths involving vulnerable road users. This data underscores a troubling increase in fatality rates. Therefore, the rising incidence of road accidents is fueling the growth of the antifibrinolytic drugs market.

An increasing number of surgical procedures is expected to propel the growth of the antifibrinolytic drugs market going forward. Surgical procedures are rising due to several reasons, including advancements in medical technology, an aging population, increased awareness, and cultural and social factors. Antifibrinolytic drugs help reduce bleeding during surgery by preventing the breakdown of blood clots, leading to improved hemostasis and potentially decreasing the need for blood transfusions. For instance, in September 2023, according to the Global Survey 2022 report released by the International Society of Aesthetic Plastic Surgery, a US-based professional body of aesthetic plastic surgeons, plastic surgery procedures saw an 11.2% overall increase in 2022, with over 14.9 million surgeries globally, including a 41.3% rise in aesthetic surgery over four years, and liposuction remained the most common surgical procedure in both 2022 and 2021. Therefore, the increasing number of surgical procedures is driving the growth of the antifibrinolytic drugs market.

Major companies in the antifibrinolytic drugs market are focusing on innovative solutions, such as a first-to-consumer approach, to offer more accessible treatments for women. This approach involves marketing these medications directly to patients rather than through traditional healthcare providers. For example, in May 2024, Maxwellia Ltd., a UK-based healthcare company, launched two new pharmacy brands, Evana Heavy Period Relief 500 mg tablets and Ultravana Period Pain Relief 250 mg gastro-resistant tablets. Evana helps reduce heavy menstrual bleeding by up to 60%, while Ultravana provides effective relief for period pain. Both are available over the counter in UK pharmacies. These products are significant in improving women's health by addressing common yet often overlooked menstrual issues and empowering women to manage their symptoms more effectively.

Major companies operating in the antifibrinolytic drugs market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Bayer AG, DAIICHI SANKYO COMPANY LIMITED, Sun Pharmaceutical Industries Ltd, Takeda Pharmaceuticals, Aurobindo Pharma Limited, Cipla Limited, Intas Pharmaceuticals, Lupin Limited, Zydus Lifesciences Ltd., Hetero Drugs Limited, Glenmark Pharmaceuticals, Alkem Laboratories, Torrent Pharmaceuticals Ltd, Macleods Pharmaceuticals Pvt Ltd, Mankind pharma Ltd, Emcure Pharmaceuticals ltd, Bharat Serums & Vaccines Ltd, Systopic Laboratories Pvt Ltd, Ozone Pharmaceuticals Ltd, ACIC Pharmaceuticals, AmeriGen Life Sciences LLP, Life Sciences Advanced Technologies Inc., Vitruvias Therapeutics Inc.

North America was the largest region in the antifibrinolytic drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antifibrinolytic drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the antifibrinolytic drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The antifibrinolytic drugs market consists of sales of tranexamic acid, aminocaproic acid, aprotinin, epsilon-aminocaproic acid, and desmopressin. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Antifibrinolytic Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on antifibrinolytic drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for antifibrinolytic drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The antifibrinolytic drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Indication: Gynecology; Hereditary Angioedema; Fibrinolytic Response Testing; Surgeries; Other Indications
• 2) By Route Of Administration: Injectable; Oral; Topical
• 3) By End User: Hospitals And Clinics; Ambulatory Surgical Centers; Trauma Centers
• Subsegments:
• 1) By Gynecology: Menorrhagia (Heavy Menstrual Bleeding); Postpartum Hemorrhage; Endometriosis-Related Bleeding
• 2) By Hereditary Angioedema: Acute Attacks Of Hereditary Angioedema; Prophylaxis For Hereditary Angioedema
• 3) By Fibrinolytic Response Testing: Testing For Fibrinolysis Activity in Trauma; Cardiac Surgery Fibrinolytic Response Testing; Testing In Coagulation Disorders
• 4) By Surgeries: Orthopedic Surgeries; Cardiovascular Surgeries; Dental Surgeries; Neurosurgeries; Urological Surgeries
• 5) By Other Indications: Trauma and Injury-Related Bleeding; Post-Operative Bleeding Management; Hemophilia-Related Bleeding Control
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd; Bayer AG; DAIICHI SANKYO COMPANY LIMITED; Sun Pharmaceutical Industries Ltd
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Antifibrinolytic Drugs Market Characteristics

3. Antifibrinolytic Drugs Market Trends And Strategies

4. Antifibrinolytic Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Antifibrinolytic Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Antifibrinolytic Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Antifibrinolytic Drugs Market Growth Rate Analysis
• 5.4. Global Antifibrinolytic Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Antifibrinolytic Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Antifibrinolytic Drugs Total Addressable Market (TAM)

6. Antifibrinolytic Drugs Market Segmentation

• 6.1. Global Antifibrinolytic Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gynecology
• Hereditary Angiedema
• Fibrinolytic Response Testing
• Surgeries
• Other Indications
• 6.2. Global Antifibrinolytic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Injectable
• Oral
• Topical
• 6.3. Global Antifibrinolytic Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Clinics
• Ambulatory Surgical Centers
• Trauma Centers
• 6.4. Global Antifibrinolytic Drugs Market, Sub-Segmentation Of Gynecology, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Menorrhagia (Heavy Menstrual Bleeding)
• Postpartum Hemorrhage
• Endometriosis-Related Bleeding
• 6.5. Global Antifibrinolytic Drugs Market, Sub-Segmentation Of Hereditary Angioedema, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute Attacks Of Hereditary Angioedema
• Prophylaxis For Hereditary Angioedema
• 6.6. Global Antifibrinolytic Drugs Market, Sub-Segmentation Of Fibrinolytic Response Testing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Testing For Fibrinolysis Activity in Trauma
• Cardiac Surgery Fibrinolytic Response Testing
• Testing In Coagulation Disorders
• 6.7. Global Antifibrinolytic Drugs Market, Sub-Segmentation Of Surgeries, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Orthopedic Surgeries
• Cardiovascular Surgeries
• Dental Surgeries
• Neurosurgeries
• Urological Surgeries
• 6.8. Global Antifibrinolytic Drugs Market, Sub-Segmentation Of Other Indications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Trauma and Injury-Related Bleeding
• Post-Operative Bleeding Management
• Hemophilia-Related Bleeding Control

7. Antifibrinolytic Drugs Market Regional And Country Analysis

• 7.1. Global Antifibrinolytic Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Antifibrinolytic Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Antifibrinolytic Drugs Market

• 8.1. Asia-Pacific Antifibrinolytic Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Antifibrinolytic Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Antifibrinolytic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Antifibrinolytic Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Antifibrinolytic Drugs Market

• 9.1. China Antifibrinolytic Drugs Market Overview
• 9.2. China Antifibrinolytic Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Antifibrinolytic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Antifibrinolytic Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Antifibrinolytic Drugs Market

• 10.1. India Antifibrinolytic Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Antifibrinolytic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Antifibrinolytic Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Antifibrinolytic Drugs Market

• 11.1. Japan Antifibrinolytic Drugs Market Overview
• 11.2. Japan Antifibrinolytic Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Antifibrinolytic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Antifibrinolytic Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Antifibrinolytic Drugs Market

• 12.1. Australia Antifibrinolytic Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Antifibrinolytic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Antifibrinolytic Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Antifibrinolytic Drugs Market

• 13.1. Indonesia Antifibrinolytic Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Antifibrinolytic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Antifibrinolytic Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Antifibrinolytic Drugs Market

• 14.1. South Korea Antifibrinolytic Drugs Market Overview
• 14.2. South Korea Antifibrinolytic Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Antifibrinolytic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Antifibrinolytic Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Antifibrinolytic Drugs Market

• 15.1. Western Europe Antifibrinolytic Drugs Market Overview
• 15.2. Western Europe Antifibrinolytic Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Antifibrinolytic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Antifibrinolytic Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Antifibrinolytic Drugs Market

• 16.1. UK Antifibrinolytic Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Antifibrinolytic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Antifibrinolytic Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Antifibrinolytic Drugs Market

• 17.1. Germany Antifibrinolytic Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Antifibrinolytic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Antifibrinolytic Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Antifibrinolytic Drugs Market

• 18.1. France Antifibrinolytic Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Antifibrinolytic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Antifibrinolytic Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Antifibrinolytic Drugs Market

• 19.1. Italy Antifibrinolytic Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Antifibrinolytic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Antifibrinolytic Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Antifibrinolytic Drugs Market

• 20.1. Spain Antifibrinolytic Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Antifibrinolytic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Antifibrinolytic Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Antifibrinolytic Drugs Market

• 21.1. Eastern Europe Antifibrinolytic Drugs Market Overview
• 21.2. Eastern Europe Antifibrinolytic Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Antifibrinolytic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Antifibrinolytic Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Antifibrinolytic Drugs Market

• 22.1. Russia Antifibrinolytic Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Antifibrinolytic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Antifibrinolytic Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Antifibrinolytic Drugs Market

• 23.1. North America Antifibrinolytic Drugs Market Overview
• 23.2. North America Antifibrinolytic Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Antifibrinolytic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Antifibrinolytic Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Antifibrinolytic Drugs Market

• 24.1. USA Antifibrinolytic Drugs Market Overview
• 24.2. USA Antifibrinolytic Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Antifibrinolytic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Antifibrinolytic Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Antifibrinolytic Drugs Market

• 25.1. Canada Antifibrinolytic Drugs Market Overview
• 25.2. Canada Antifibrinolytic Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Antifibrinolytic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Antifibrinolytic Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Antifibrinolytic Drugs Market

• 26.1. South America Antifibrinolytic Drugs Market Overview
• 26.2. South America Antifibrinolytic Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Antifibrinolytic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Antifibrinolytic Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Antifibrinolytic Drugs Market

• 27.1. Brazil Antifibrinolytic Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Antifibrinolytic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Antifibrinolytic Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Antifibrinolytic Drugs Market

• 28.1. Middle East Antifibrinolytic Drugs Market Overview
• 28.2. Middle East Antifibrinolytic Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Antifibrinolytic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Antifibrinolytic Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Antifibrinolytic Drugs Market

• 29.1. Africa Antifibrinolytic Drugs Market Overview
• 29.2. Africa Antifibrinolytic Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Antifibrinolytic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Antifibrinolytic Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Antifibrinolytic Drugs Market Competitive Landscape And Company Profiles

• 30.1. Antifibrinolytic Drugs Market Competitive Landscape
• 30.2. Antifibrinolytic Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. DAIICHI SANKYO COMPANY LIMITED Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sun Pharmaceutical Industries Ltd Overview, Products and Services, Strategy and Financial Analysis

31. Antifibrinolytic Drugs Market Other Major And Innovative Companies

• 31.1. Takeda Pharmaceuticals
• 31.2. Aurobindo Pharma Limited
• 31.3. Cipla Limited
• 31.4. Intas Pharmaceuticals
• 31.5. Lupin Limited
• 31.6. Zydus Lifesciences Ltd.
• 31.7. Hetero Drugs Limited
• 31.8. Glenmark Pharmaceuticals
• 31.9. Alkem Laboratories
• 31.10. Torrent Pharmaceuticals Ltd
• 31.11. Macleods Pharmaceuticals Pvt Ltd
• 31.12. Mankind Pharma Ltd
• 31.13. Emcure Pharmaceuticals Ltd
• 31.14. Bharat Serums & Vaccines Ltd
• 31.15. Systopic Laboratories Pvt Ltd

32. Global Antifibrinolytic Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Antifibrinolytic Drugs Market

34. Recent Developments In The Antifibrinolytic Drugs Market

35. Antifibrinolytic Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Antifibrinolytic Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Antifibrinolytic Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Antifibrinolytic Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer
• 250423_r33396_Antifibrinolytic_Drugs_GMR_2025